BIO-FD&C Co.,Ltd. (KOSDAQ:251120)
South Korea · Delayed Price · Currency is KRW 13,420
-460 (-3.31%)
At close: Apr 2, 2026
BIO-FD&C Revenue
In the year 2025, BIO-FD&C had annual revenue of 19.18B KRW with 19.37% growth. BIO-FD&C had revenue of 5.10B in the quarter ending December 31, 2025, with 7.65% growth.
Revenue
19.18B
Revenue Growth
+19.37%
P/S Ratio
6.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
116.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.18B | 3.11B | 19.37% |
| Dec 31, 2024 | 16.07B | 474.34M | 3.04% |
| Dec 31, 2023 | 15.59B | -263.23M | -1.66% |
| Dec 31, 2022 | 15.86B | 3.88B | 32.43% |
| Dec 31, 2021 | 11.97B | 3.33B | 38.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| KoBioLabs | 69.29B |
| Cell Biotech | 53.13B |
| CORESTEMCHEMON | 20.16B |
| QuadMedicine | 13.11B |
| TegoScience | 5.94B |
| Quratis | 2.46B |
| NovMetaPharma | 1.30B |